Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer - Report - MDSpire

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • By

  • June 24, 2026

  • 4 min

Share

Clinical Report: FDA Approval of Sacituzumab Govitecan for TNBC

Overview

The FDA has approved sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer (TNBC), based on the ASCENT-03 and ASCENT-04 trials. These studies demonstrated improvements in progression-free survival compared to standard chemotherapy.

Background

Triple-negative breast cancer is an aggressive subtype, accounting for approximately 15% of breast cancer cases, with a five-year survival rate of 12% for metastatic cases. The approval of sacituzumab govitecan provides a new treatment option for patients who are ineligible for immune checkpoint inhibitors.

Data Highlights

StudyMedian PFS (months)Response Duration (months)
ASCENT-03 (monotherapy)9.712.2
ASCENT-04 (combination)11.216.6

Key Findings

  • The ASCENT-03 trial showed a median progression-free survival (PFS) of 9.7 months for sacituzumab govitecan versus 6.9 months for chemotherapy.
  • In ASCENT-04, the combination of sacituzumab govitecan and pembrolizumab resulted in an 11.2 month median PFS compared to 7.8 months for chemotherapy plus pembrolizumab.
  • Nearly 60% of patients responded to the sacituzumab govitecan and pembrolizumab combination.
  • Patients receiving sacituzumab govitecan had a median duration of response of 16.6 months compared to 9.2 months for chemotherapy.

Clinical Implications

The approval of sacituzumab govitecan as a first-line therapy provides oncologists with a new option for treating metastatic TNBC, particularly for patients who cannot receive checkpoint inhibitors.

Conclusion

The FDA's approval of sacituzumab govitecan marks a milestone in the treatment of metastatic triple-negative breast cancer.

Related Resources & Content

  1. Dana-Farber, FDA, 2026 -- FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
  2. Dana-Farber, ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer, 2026
  3. Nature Reviews Clinical Oncology, 2025 -- Frontline sacituzumab govitecan prolongs PFS in TNBC
  4. dana-farber — Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
  5. conexiant — FDA Approves New First-Line TNBC Regimen
  6. dana-farber — Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
  7. Survival improvements observed with first-line ADCs in TNBC
  8. FDA Approves New First-Line TNBC Regimen
  9. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer | FDA
  10. Frontline sacituzumab govitecan prolongs PFS in TNBC | Nature Reviews Clinical Oncology
  11. KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC) - Merck.com
  12. Sacituzumab govitecan plus pembrolizumab improves outcomes | Nature Reviews Clinical Oncology
  13. Sacituzumab Govitecan With Pembrolizumab Extends Progression-Free Survival 2 for Some People With Metastatic Triple-Negative Breast Cancer - ASCO
  14. NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
  15. Trodelvy® Added as Preferred Regimen Within First-Line Metastatic Triple-Negative Breast Cancer in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
  16. NCCN Adds Trodelvy as Preferred First-Line Option in Metastatic Triple-Negative Breast Cancer
  17. Sacituzumab Govitecan Helps Some Patients With PD-L1-Positive Triple-Negative Breast Cancer Live Longer Without Cancer Progression - ASCO

Original Source(s)

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

  • by

  • June 24, 2026

Related Content

Surviving CGT's Funding Winter

In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

  • July 1, 2026

  • 1 min
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min